ImmunoCellular cut in half as ICT-107 misses primary OS endpoint

Dec. 11, 2013 4:23 PM ETEOM Pharmaceuticals Holdings, Inc. (IMUC)IMUCBy: Colin Lokey, SA News Editor6 Comments
  • ImmunoCellular (OTCPK:IMUC) collapses 50% AH.
  • The company is out with results from a Phase 2 study of ICT-107 in newly diagnosed glioblastoma multiforme.
  • ICT-107 showed statistically significant PFS superiority over placebo. K-M curves (entire sample of 124 patients): Favors ICT-107; HR of 0.56; p=0.014; median PFS increase was two months. K-M curves (per-protocol population): Favors ICT-107; HR of 0.53; p=0.0074; median PFS increase was three months.
  • OS K-M curves fail to hit statistical significance. OS was the primary endpoint. Summary (intent-to-treat): HR of 0.87; p=0.58. Summary (per-protocol): HR of 0.79; p=0.40.
  • For more, see here.

Recommended For You

Comments (6)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.